Pricing Log in Create free account

Greenwich LifeSciences, Inc. (GLSI) vs Lineage Cell Therapeutics, Inc. (LCTX)

Greenwich LifeSciences, Inc. and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. is the larger, with a market value of $250.5M against $224.9M — 1.1× the size. Greenwich LifeSciences, Inc. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 14 metrics below, Greenwich LifeSciences, Inc. leads on 9 and Lineage Cell Therapeutics, Inc. on 5.

Valuation

Metric GLSI LCTX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 18.69 9.71
P/B 68.25 4.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 14.81 9.21
Earnings yield (10.58%) (14.67%) (33.15%)
Free cash flow yield (5.87%) (9.98%) (25.50%)

Profitability

Metric GLSI LCTX Biotechnology median
Gross margin 0.00% 99.46% 65.16%
Operating margin 0.00% (205.23%) 0.00%
Net margin 0.00% (246.58%) 0.00%
Free cash flow margin 0.00% (186.43%) 0.00%
Return on equity (986.31%) (60.35%) (56.36%)
Return on assets (374.46%) (32.75%) (48.04%)
Return on invested capital 0.00% (186.79%) 0.00%

Growth

Metric GLSI LCTX Biotechnology median
Revenue growth (TTM) — 19.87% 6.02%
EPS growth (last fiscal year) (18.18%) (211.11%) 30.26%
Revenue growth, 5-year CAGR — 51.46% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLSI LCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.54 6.61 4.72
Net debt to EBITDA 0.32 2.64 0.96

Dividend

Metric GLSI LCTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GLSI LCTX Biotechnology median
Market cap 224.87m 250.45m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack